THC Biomed Intl Ltd. (THCBF) Stock Analysis

THC Biomed Intl Ltd. (THCBF) Healthcare & Pipeline Overview

THC Biomed Intl Ltd. is a Canadian cannabis company focused on producing and distributing medical and recreational cannabis products, including beverages, edibles, and pure cannabis sticks under the THC KISS brand, operating in a competitive and evolving regulatory landscape with a current negative profit margin.

What Is the Investment Thesis for THCBF?

Investing in THC Biomed Intl Ltd. (THCBF) presents a high-risk, high-reward scenario. The company's negative profit margin of -91.8% and gross margin of -30.8% indicate significant challenges in achieving profitability. Growth catalysts include potential expansion of its product line and increased market penetration within Canada. However, the company's small market capitalization and negative beta of -0.36 suggest high volatility and sensitivity to market fluctuations. The absence of a dividend further underscores the speculative nature of this investment. Investors should carefully consider the company's financial performance, competitive landscape, and regulatory risks before investing.

Based on FMP financials and quantitative analysis

THCBF Key Highlights

Market Cap of $0.00B indicates a micro-cap company with limited resources and higher volatility.

• P/E Ratio of -1.07 reflects negative earnings, suggesting the company is currently not profitable.
• Profit Margin of -91.8% highlights significant challenges in achieving profitability and managing expenses.
• Gross Margin of -30.8% indicates that the company's cost of goods sold exceeds its revenue, raising concerns about its pricing strategy and operational efficiency.
• Beta of -0.36 suggests the stock price is negatively correlated with the market, potentially offering downside protection during market downturns but also limiting upside potential during bull markets.

Who Are THCBF's Competitors?

THCBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are THCBF's Key Strengths?

Established brand presence with THC KISS products.

• Early mover advantage in the Canadian cannabis market.
• Diverse product portfolio including beverages, edibles, and cannabis sticks.
• Production and distribution capabilities within Canada.

What Are THCBF's Weaknesses?

Negative profit margin and gross margin.

• Small market capitalization and limited financial resources.
• High dependence on the Canadian market.
• Limited brand recognition compared to larger competitors.

What Could Drive THCBF Stock Higher?

Potential expansion of product line with new cannabis-infused beverages and edibles.

• Increasing market penetration in Canada through expanded distribution network.
• Development of medical cannabis products for specific conditions and ailments.
• Strategic partnerships and acquisitions to expand capabilities and market reach.
• Exploration of international expansion opportunities in countries with legal cannabis markets.

What Are the Key Risks for THCBF?

Financial-distress signal — its Altman Z-Score of -3.68 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-36.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Intense competition from larger, more established cannabis companies.
• Evolving regulations and changing consumer preferences.
• Increased taxes and regulatory burdens on the cannabis industry.
• Fluctuations in cannabis prices and supply.
• Limited access to capital and financing options.

What Are the Growth Opportunities for THCBF?

• Expansion of Product Line: THC Biomed can expand its product line to include new and innovative cannabis products, such as infused beverages, edibles, and topicals. The market for cannabis-infused products is growing rapidly, driven by increasing consumer demand for alternative consumption methods. By introducing new and differentiated products, THC Biomed can attract new customers and increase its market share. The timeline for this growth opportunity is immediate, as the company can begin developing and launching new products in the near term. Success depends on effective product development, marketing, and regulatory compliance.
• Increased Market Penetration in Canada: THC Biomed can increase its market penetration within Canada by expanding its distribution network and marketing efforts. The Canadian cannabis market is still relatively young, and there is significant potential for growth. By reaching more consumers and increasing brand awareness, THC Biomed can increase its sales and revenue. The timeline for this growth opportunity is ongoing, as the company can continuously expand its reach and marketing efforts. Success depends on effective distribution strategies, marketing campaigns, and partnerships with retailers.
• Development of Medical Cannabis Products: THC Biomed can focus on developing and marketing medical cannabis products for specific conditions and ailments. The medical cannabis market is growing as more research emerges on the therapeutic benefits of cannabis. By developing targeted medical cannabis products, THC Biomed can cater to patients seeking alternative treatments and increase its revenue. The timeline for this growth opportunity is medium-term, as the company needs to conduct research, develop formulations, and obtain regulatory approvals. Success depends on scientific research, product development, and regulatory compliance.
• Strategic Partnerships and Acquisitions: THC Biomed can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. By partnering with other companies in the cannabis industry, THC Biomed can gain access to new technologies, distribution networks, and markets. Acquisitions can also provide THC Biomed with access to new products, brands, and customer bases. The timeline for this growth opportunity is medium- to long-term, as it depends on identifying suitable partners and acquisition targets. Success depends on effective due diligence, negotiation, and integration.
• International Expansion: THC Biomed can explore opportunities for international expansion, particularly in countries with legal cannabis markets. The global cannabis market is growing rapidly, and there is significant potential for companies to expand their operations internationally. By entering new markets, THC Biomed can diversify its revenue streams and reduce its reliance on the Canadian market. The timeline for this growth opportunity is long-term, as it requires careful planning, regulatory compliance, and market research. Success depends on understanding local regulations, consumer preferences, and competitive landscapes.

What Are THCBF's Competitive Advantages?

• Brand recognition through the THC KISS brand.
• Established distribution network in Canada.
• Proprietary formulations for cannabis-infused products.
• Early mover advantage in the Canadian cannabis market.

What Does THCBF Do?

THC Biomed Intl Ltd., founded in 2012 and headquartered in Kelowna, Canada, is a cannabis company focused on the production and sale of medical and recreational cannabis. The company's product portfolio includes a variety of cannabis products, such as cannabis beverage shots, gummies, and biscuits marketed under the THC KISS brand. Additionally, THC Biomed offers pure cannabis sticks. The company operates within the Canadian cannabis market, navigating a complex regulatory environment. THC Biomed's strategy involves developing and marketing diverse cannabis products to cater to both medical and recreational users. The company aims to establish a strong brand presence in the Canadian market through its THC KISS line and other product offerings. As a relatively small player in the broader cannabis industry, THC Biomed faces competition from larger, more established companies. The company's success depends on its ability to innovate, maintain product quality, and effectively market its products to consumers and medical patients. THC Biomed continues to explore opportunities for growth and expansion within the evolving Canadian cannabis market.

What Products and Services Does THCBF Offer?

• Produces and sells medical cannabis in Canada.
• Produces and sells recreational cannabis in Canada.
• Offers cannabis beverage shots under the THC KISS brand.
• Offers cannabis gummies under the THC KISS brand.
• Offers cannabis biscuits under the THC KISS brand.
• Offers pure cannabis sticks.

How Does THCBF Make Money?

• Cultivates and processes cannabis.
• Manufactures cannabis-infused products.
• Distributes products through authorized retailers.
• Generates revenue through the sale of cannabis and cannabis-infused products.

What Industry Does THCBF Operate In?

THC Biomed Intl Ltd. operates within the rapidly evolving Canadian cannabis industry. The market is characterized by increasing competition, evolving regulations, and shifting consumer preferences. Companies in this sector face challenges related to production costs, distribution, and marketing. The Canadian cannabis market is projected to continue growing, driven by increasing acceptance and legalization of cannabis products. THC Biomed competes with larger, more established players in the industry, including companies with greater financial resources and broader distribution networks. The company's success depends on its ability to differentiate its products, effectively manage costs, and navigate the complex regulatory landscape.

Who Are THCBF's Key Customers?

• Medical cannabis patients in Canada.
• Recreational cannabis consumers in Canada.
• Authorized cannabis retailers in Canada.

Wall Street analysts project THC Biomed Intl Ltd. revenue of about $3.1M for fiscal 2026, with EPS near $-0.02.

Return on equity for THC Biomed Intl Ltd. stands at -36.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -20.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -61.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.63 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -93.5%, the inverse of the P/E and a quick read on earnings relative to price.

THC Biomed Intl Ltd.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.68 places it in the distress zone, a signal of elevated financial risk.

Company Profile

THC Biomed Intl Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Kelowna, CA. The company is led by CEO John Miller. THCBF has traded publicly since 2018.

THCBF Financials

THCBF Latest News

No recent news available for THCBF.

THCBF Analyst Consensus

THCBF MoonshotScore

What Investors Ask About THC Biomed Intl Ltd. (THCBF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources